#

Pharmaceutical Companies

: 153
Eli Lilly has once again expanded its portfolio of potential new drugs this year / Photo: Tada Images/Shutterstock.com
News·
Eli Lilly has found a new acquisition target. The company has already spent $20 billion this year
BioNTech and Roche have halted trials of an experimental personalized mRNA immunotherapy for patients with stage II–III colorectal cancer / Photo: Kittyfly / Shutterstock.com
News·
BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?
Moderna will use the proceeds to fund the development of a cancer drug and to pay off debt / Photo: Shutterstock.com / Dmitriy Melnikov
News·
Moderna to Raise $2 Billion Following a Surge in Its Stock Price — Including Funding for a Cancer Vaccine
Photo: Kittyfly/Shutterstock
News·
Deutsche Bank recommended selling Novo Nordisk shares after they fell 70% from their peak
The Japanese pharmaceutical company Takeda is ready to launch a revolutionary drug for the treatment of sleep disorders. Photo: Solving Healthcare/Unsplash.com
Review·
Orexins—the Next Ozempic? The Pharmaceutical Industry Prepares for a Breakthrough in Neuroscience
Photo: Andrei Doronichevs personal archive.
Review·
Five biotech companies that Andrei Doronichev is keeping an eye on
Modernas 177% stock surge led to multibillion-dollar paper losses for short sellers / Photo: Shutterstock.com / Tada Images
News·
Moderna's stock price nearly tripled, resulting in $5.5 billion in paper losses for short sellers
Amylyx Pharmaceuticals surged after its drug candidate, avexitide, met primary and secondary endpoints in a phase III clinical trial / Photo: Unsplash/Julia Koblitz
Small Caps·
Mid-cap biotech Amylyx jumps 60% after drug meets endpoints in late-stage trial
Andrey Doronichevs startup, Bioptic, is currently raising a new round of funding / Photo: Evgenia Eliseeva / Andrey Doronichevs personal archive
News·
Andrey Doronichev's biotech startup, Bioptic, is considering an IPO
Photo: Evgenia Eliseeva / Andrei Doronichevs personal archive
Review·
'New leaders will rise from the ashes': An interview with Andrey Doronichev
The companys experimental shot reduced the frequency and severity of hot flashes over a four-week study compared with a placebo, with no serious side effects / Photo: AbCellera
Small Caps·
Mid-cap hot-flash drugmaker AbCellera soars on upbeat mid-stage clinical data
Sionna will now shelve its cystic fibrosis drug candidate / Photo: LinkedIn/Sionna Therapeutics
Small Caps·
Sionna's cystic fibrosis drug candidate fails in trial; stock craters 90%
Load more